tetano
Editor, Senior Moderator
Intern Med
. 2020 Sep 19.
doi: 10.2169/internalmedicine.5244-20. Online ahead of print.
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
Hideta Nakamura[SUP] 1 [/SUP], Kazuya Miyagi[SUP] 1 [/SUP], Mariko Otsuki[SUP] 1 [/SUP], Yuri Higure[SUP] 1 [/SUP], Naoya Nishiyama[SUP] 1 [/SUP], Takeshi Kinjo[SUP] 1 [/SUP], Masashi Nakamatsu[SUP] 1 [/SUP], Shusaku Haranaga[SUP] 1 [/SUP], Masao Tateyama[SUP] 1 [/SUP], Jiro Fujita[SUP] 1 [/SUP]
Affiliations
Abstract
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
Keywords: COVID-19; acute hypertriglyceridaemia; tocilizumab.
. 2020 Sep 19.
doi: 10.2169/internalmedicine.5244-20. Online ahead of print.
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
Hideta Nakamura[SUP] 1 [/SUP], Kazuya Miyagi[SUP] 1 [/SUP], Mariko Otsuki[SUP] 1 [/SUP], Yuri Higure[SUP] 1 [/SUP], Naoya Nishiyama[SUP] 1 [/SUP], Takeshi Kinjo[SUP] 1 [/SUP], Masashi Nakamatsu[SUP] 1 [/SUP], Shusaku Haranaga[SUP] 1 [/SUP], Masao Tateyama[SUP] 1 [/SUP], Jiro Fujita[SUP] 1 [/SUP]
Affiliations
- PMID: 32963155
- DOI: 10.2169/internalmedicine.5244-20
Abstract
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
Keywords: COVID-19; acute hypertriglyceridaemia; tocilizumab.